This rate may differ according to the anatomical location of the tumor: intrahepatic cholangiocarcinoma is generally associated with a significantly lower rate of KRAS mutation than that observed in patients with extrahepatic cholangiocarcinoma (7–22% vs. 37–46%, respectively) [7,8,9]. The gene discussed is KRAS; the disease is neoplasm.